Safety of proteasome inhibitor drugs for the treatment of multiple myeloma post-marketing: a pharmacovigilance investigation based on the FDA adverse event reporting system-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety of proteasome inhibitor drugs for the treatment of multiple myeloma post-marketing: a pharmacovigilance investigation based on the FDA adverse event reporting system

Published:2024-08-19 Issue: Volume: Page:
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Yu Dongdong¹^ORCID,Cheng Ting²^ORCID,Liu Tong³,Xu Wenjun¹,Liu Dawei¹,Dai Jinzhi¹,Cai Shanshan¹,Guan Yuxiang⁴,Ye Ting⁵^ORCID,Cheng Xiaoyu¹^ORCID

Affiliation:

1. The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei City, Anhui province, China

2. Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou City, Guangdong province, China

3. School of Traditional Chinese Medicine, Anhui University of Chinese Medicine, Hefei City, Anhui province, China

4. School of Nursing, Anhui University of Chinese Medicine, Hefei City, Anhui province, China

5. School of Integrated Chinese and Western Medicine, Anhui University of Chinese Medicine, Hefei City, Anhui province, China

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2024.2393275

Reference32 articles.

1. Cancer statistics, 2023

2. Multiple myeloma

3. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

4. NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022

5. Proteasome Inhibitors: Harnessing Proteostasis to Combat Disease

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP